The effects of helper T-cell clone supernatants on resting human B cells were investigated. Four different helper T-cell clones (two T4' and two T8+) were stimulated by anti-T3 monoclonal antibodies on Sepharose beads or anti-T112 plus anti-T113 monoclonal antibodies. The supernatants from these activated clones induced the proliferation of highly purified resting B lymphocytes from the peripheral blood. The B cells exhibited a cell size and a surface-antigen pattern (4F2 antigen and transferrin receptor) of phase Go B cells, and they were functionally resting. In response to T-cell supernatants a large fraction of the B cells enlarged and expressed 4F2 antigens and transferrin receptors. In gel filtration, the corresponding activity migrated with an apparent Mr of 12,000-15,000. Our fwdings strongly support the existence of a human B-cell-activating factor acting on resting B cells and causing them to enter phase G1 of the cell cycle.
antibodies or Staphylococcus aureus Cowan A strain (SAC) that are supposed to polyclonally activate resting B cells. Interleukin 2 (IL-2) also induces proliferation and, in some cases, differentiation of SAC or anti-,-activated human B cells (7) . In addition, a direct effect of very high doses of IL-2 on unstimulated B cells (8) was also reported.
In the mouse model, we have shown that the T cells can be replaced by their supernatant for mouse resting B-cell activation, proliferation, and differentiation (9) (10) (11) . We have hypothesized that a new lymphokine called B-cell-activating factor (BCAF) was responsible for resting B-cell activation, and we now have evidence that this factor is distinct from other mouse lymphokines. In this report, we extend these observations to the human model. Using helper T-cell clones stimulated by anti-T3 or anti-T11 monoclonal antibodies (mAbs), we have produced supernatants that could polyclonally activate highly purified resting human B cells from the peripheral blood. Our findings strongly support the existence of a human BCAF with an apparent Mr of 12,000-15,000.
MATERIALS AND METHODS B-Cell Preparation and Proliferation Assay. Peripheral blood mononuclear cells were obtained by Ficoll/Hypaque (Pharmacia, Paris) density-gradient centrifugation of peripheral blood from healthy adult volunteers and were partially depleted of adherent cells by adherence to plastic culture dishes. Nonadherent cells were submitted to rosette formation with neuraminidase-treated sheep erythrocytes, and nonrosetting cells were recovered after centrifugation on a Lymphoprep gradient (Nyegaard, Oslo). The B cells were then separated by using a discontinuous gradient of Percoll (Pharmacia) as described (12) , and cells banding at the interface between Percoll concentrations 50o and 60% were collected. These preparations (referred to as dense B cells) routinely contained <1% T cells, 2-3% monocytes, and >85% B cells as determined by immunofluorescence staining using anti-T4 plus anti-T8, MO1, and anti-Bi mAbs, respectively (21, 22) . The B-cell preparations showed no proliferative response to T-cell mitogens such as phytohemagglutinin (PHA), concanavalin A, or anti-T112 plus anti-T113 mAbs. T-Cell Clones. P2 and N2 (T8+) were cloned twice by limiting dilution methods, in which T cells from a healthy volunteer (0.3 cell per well) were plated in the presence of irradiated autologous feeder layers in IL-2-containing medium with 0.25 ,ug of PHA per ml (Wellcome). Tetanus toxoid-specific T-cell clones TT1 and TT9 (T4+) were obtained in the same way from an antigen-specific cell line raised from T cells of a healthy volunteer using tetanus toxoid at 0.3 floculation unit/ml (Massachusetts State Biological Laboratories, Jamaica Plain, MA). T cells were cultured in IL-2-containing medium. Restimulation was done every 4 weeks in the presence of irradiated feeder cells, PHA (0.25 ,tg/ml), and IL-2. The T-cell cultures tested negatively for mycoplasma at least twice during the course of this work.
Production ofT-Cell Supernatants. T-cell clones were taken 15 days after restimulation, washed once, and incubated in 5 ml of polypropylene tubes (Falcon) at 106 cells/ml for 6 hr or 24 hr at 37°C in medium alone, or in the presence of anti-T3 mAbs on Sepharose beads (1/50) (13) , or a combination of anti-T112 plus anti-T113 mAbs (1/200 dilution of ascitic fluid) (14) . The supernatants were then collected, filtered through a 0. 22-,um The culture supernatants were collected and as& cultures. As shown in Fig. 1, (3, shows that when these lymphokines were ass small B cells, no significant proliferative respc However, when anti-IL antibodies coupled beads were added to the cultures, the same co to all three lymphokines. We also verified tha and y-interferon do not induce any proliferati cells (data not shown). (P2 and N2) IL-2-dependent T-cell line), it was of interest to evaluate the on Sepharose contribution of IL-2 to our results. The final concentration of iti-T113 mAbs.
IL-2 from P2(Tll)-SN in the B-cell assays (between 0.6 and sayed in B-cell 1.25 ng/ml) was too low to account by itself for the observed are driven to response (Table 1) . We further excluded the participation of ipernatants, in IL-2 in the effects of the T-cell supernatant by either blocking I this effect is the IL-2 receptor or neutralizing the IL-2 activity with rative activity appropriate mAbs. As shown in Table 2 10 experimental conditions described in Table 2 of the T81 phenotype have already been described (18) . The T-cell clones could be activated through either the T3-T-cell receptor complex (13) , or more efficiently through the Til alternative pathway (14) . Activation of T cells with mAbs was done at a time where all feeder cells had been eliminated from the cultures. The factors found in the supernatant must, therefore, be secreted by T cells themselves.
The responding cell population consisted of highly purified B lymphocytes and did not show any response to T-cell mitogens. In addition, the proportion of cells bearing B-cell markers remained constant over the 3-day culture period with T-cell supernatant (data not shown). In all experiments, resting B cells were separated according to cell density on a Percoll gradient (12) , and dense B cells were used in the cultures. Different criteria were used to verify the state of activation of the responding B-cell population. The size profile and the surface antigen pattern (transferrin receptor and 4F2 antigen) of the dense B cells were consistent with cells in phase Go of the cell cycle (17) . In addition, the B cells were functionally resting because they failed to proliferate in response to low-Mr BCGF, IL-4, and IL-2. Several controls in the experiments also excluded an activation of B cells due to culture conditions ( Fig. 2A and data not shown) .
Our main observation is that supernatants from T-cell clones act on resting B-cell populations independently of additional stimuli, such as anti-,a or SAC. Such supernatants induce surface-activation antigens, blastogenesis, and thymidine uptake in the culture. By using parameters that can be measured on each cell individually, we saw that at least 50o of the B cells undergo marked changes in size or in surfaceantigen expression in response to T-cell factors.
The resting B-cell proliferative activity was recovered after gel filtration in the 12,000-15,000 Mr range. We can therefore exclude a requirement for high-Mr BCGF in our results but not of low-Mr BCGF or IL-4, both of which have a reported Mr of -15,000. These two factors do not induce the prolif- 
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eration of resting B cells (Table 1 and refs. 3, 6 ), but we cannot exclude their participation in the observed proliferative response. IL-2 at moderate concentrations only acts on preactivated B cells (7), but IL-2 was reported to have a direct effect on resting B cells at high concentrations (>100 ng/ml) (8) . The use of two different types of mAbs, one directed at the IL-2 receptor (33B3-1) and the other one directed at soluble IL-2 (DMS-1) allowed us to exclude any participation of IL-2 in our results.
Our results strongly support the existence of a T-cellderived soluble factor that acts early in resting B-cell activation. This BCAF could either induce the proliferation of resting B cells or prepare the B cells to respond to other lymphokines such as BCGF or IL-4. We have already described a factor for mouse resting B lymphocytes with (19) and supernatant of a T-cell hybridoma (20) induce the proliferation of tonsillar B cells. These observations, as well as our results in the human and mouse system, all suggest the existence of a BCAF. This remains an hypothesis until complete biochemical characterization of such a factor. We cannot exclude that a combination of already known lymphokines may account for our results, although this has never been reported.
BCAF-containing supernatant acts in the absence of Tcell-B-cell contact and activates B cells independently of their major histocompatibility complex antigens and specificity. This activation suggests that resting B lymphocytes can respond to lymphokines independently of surface immunoglobulin cross-linking or Ia recognition by helper T cells. It is important to examine the consequences of such an activation pathway on the specificity of the B-cell immune response. Because helper T cells can only secrete this factor upon activation, one can imagine that B cells acting as antigen-presenting cells would be the first target to T-cell lymphokines. The target specificity thus would be maintained by the proximity of the antigen-specific T and B cells. However, the existence of a BCAF could explain the recruitment of bystander, unspecific B cells during an antigenspecific immune response. Purification of this lymphokine will permit a closer examination of its participation in the humoral immune response.
